Industry Symposia
Day 1 – 21 September 2021 |
|
10:30–11:30 | Industry Symposium 2 – Otsuka ![]() The International Patient and Provider Voice in IgA NephropathyModerator: Jonathan Barratt Dana Rizk, Vivekanand Jha, Adrian Liew, Bonnie Schneider, Gisela Delgado, Malkia White An international roundtable discussion amongst nephrologists, patients, and a patient caregiver about living with, managing, supporting, and educating patients with IgA nephropathy. The symposium objectives include: amplifying the global voice for patients with IgA nephropathy, highlighting similarities and differences in each patient’s journey; increasing provider understanding of patients’ perspectives on living with IgA nephropathy and how these perspectives may differ internationally; understanding how providers can support patients with IgA nephropathy and which tools need to be added to their care armamentarium; identifying cross-cultural differences in IgA nephropathy diagnosis and understanding of the disease; facilitating understanding of patients’ management for IgA nephropathy, and identify current gaps in management. |
15:00–15:30 |
Industry Symposium 6a – Novartis
Chair: Smeeta Sinha Bart Maes, Loreto Gesualdo 15:00 Welcome note An invitation to this symposium you can download here. |
18:15–19:15 | Industry Symposium 2 – Otsuka ![]() The International Patient and Provider Voice in IgA NephropathyModerator: Jonathan Barratt Dana Rizk, Vivekanand Jha, Adrian Liew, Bonnie Schneider, Gisela Delgado, Malkia White An international roundtable discussion amongst nephrologists, patients, and a patient caregiver about living with, managing, supporting, and educating patients with IgA nephropathy. The symposium objectives include: amplifying the global voice for patients with IgA nephropathy, highlighting similarities and differences in each patient’s journey; increasing provider understanding of patients’ perspectives on living with IgA nephropathy and how these perspectives may differ internationally; understanding how providers can support patients with IgA nephropathy and which tools need to be added to their care armamentarium; identifying cross-cultural differences in IgA nephropathy diagnosis and understanding of the disease; facilitating understanding of patients’ management for IgA nephropathy, and identify current gaps in management. |
19:20–20:20 | Industry Symposium 1 – Calliditas ![]() IgA nephropathy – Seeing the Bigger PictureJonathan Barratt: Gut-kidney pathophysiology and evidence for the role of the gut in IgAN |
Day 2 – 22 September 2021 |
|
Industry Symposium 3 – Chinook ![]() Novel Targets and Therapeutics for IgAN ManagementRichard Lafayette: Pathogenesis of IgAN |
|
10:20–11:20 | Industry Symposium 4 – Travere ![]() The Journey to CKD in IgA Nephropathy: The Roles of Endothelin-1, Angiotensin II, and ProteinuriaJonathan Barratt: Introduction and setting the scene An invitation to this symposium you can download here. |
14:50–15:20 | Industry Symposium 6b – Novartis ![]() The important role of the alternative complement pathway in IgANChair: Bart Maes Lisa Willcocks 14:50 Opening remarks An invitation to this symposium you can download here. |
18:05–19:05 | Industry Symposium 4 – Travere ![]() The Journey to CKD in IgA Nephropathy: The Roles of Endothelin-1, Angiotensin II, and ProteinuriaJonathan Barratt: Introduction and setting the scene An invitation to this symposium you can download here. |
19:10–20:10 |
Industry Symposium 3 – Chinook
Richard Lafayette: Pathogenesis of IgAN |
Day 3 – 23 September 2021 |
|
Industry Symposium 5 – Omeros ![]() Emerging Evidence on the Role of Lectin Pathway Inhibition in the Management of IgANObjective: To enhance awareness about the pathophysiology of IgAN and educate on the role of the lectin pathway of complement using emerging clinical evidence. Vladimir Tesar: IgAN Clinical Review: Pathophysiology and Treatment Landscape An invitation to this symposium you can download here. |
|
14:35–15:35 | Industry Symposium 5 – Omeros ![]() Emerging Evidence on the Role of Lectin Pathway Inhibition in the Management of IgANObjective: To enhance awareness about the pathophysiology of IgAN and educate on the role of the lectin pathway of complement using emerging clinical evidence. Vladimir Tesar: IgAN Clinical Review: Pathophysiology and Treatment Landscape An invitation to this symposium you can download here. |